REAL-WORLD USAGE OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH PSORIATIC ARTHRITIS IN GERMANY

被引：0
|
作者：
Song, J. [1 ,2 ]
Anjohrin, S. [3 ]
Abe, C. [4 ]
Banefelt, J. [5 ]
Rieem, Dun A. [5 ]
Picker, N. [6 ]
Kromer, D. [7 ]
Fuchs, A. [8 ]
Hahn, P. [9 ]
Welby, S. [10 ]
机构：
[1] UCB Pharma, Brussels, Belgium
[2] Karolinska Inst, Stockholm, Sweden
[3] UCB Pharma, Brussels, Belgium
[4] Karolinska Inst & Quantify Res, Stockholm, Sweden
[5] Quantify Res, Stockholm, Sweden
[6] Cytel, Wismar, Germany
[7] Cytel, Berlin, Germany
[8] AOK PLUS, Dresden, Germany
[9] Inst Pharmakookonomie & Arzneimittell IPAM, Wismar, Germany
[10] UCB Pharma, Anderlecht, Belgium
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HSD60
引用
收藏
页码：S305 / S305
页数：1
相关论文
共 50 条
  • [21] RHEUMATOID-ARTHRITIS - DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    KIRWAN, JR
    CURREY, HLF
    CLINICS IN RHEUMATIC DISEASES, 1983, 9 (03): : 581 - 599
  • [22] Cardiovascular Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
    Drakopoulou, Maria
    Soulaidopoulos, Stergios
    Oikonomou, George
    Tousoulis, Dimitrios
    Toutouzas, Konstantinos
    CURRENT VASCULAR PHARMACOLOGY, 2020, 18 (05) : 488 - 506
  • [23] Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study
    Ylenia Ingrasciotta
    Yinzhu Jin
    Saveria S. Foti
    Joan E. Landon
    Michele Tari
    Francesco Mattace-Raso
    Seoyoung C. Kim
    Gianluca Trifirò
    Clinical Rheumatology, 2023, 42 : 1047 - 1059
  • [24] Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study
    Ingrasciotta, Ylenia
    Jin, Yinzhu
    Foti, Saveria S. S.
    Landon, Joan E. E.
    Tari, Michele
    Mattace-Raso, Francesco
    Kim, Seoyoung C. C.
    Trifiro, Gianluca
    CLINICAL RHEUMATOLOGY, 2023, 42 (04) : 1047 - 1059
  • [25] Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis
    Min, Hong Ki
    Kim, Se Hee
    Kim, Hae-Rim
    Lee, Sang-Heon
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [26] STRATEGIES FOR THE USE OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PSORIATIC ARTHRITIS, INCLUDING TREAT TO TARGET
    Helliwell, Philip
    RHEUMATOLOGY, 2016, 55 : 22 - 22
  • [27] Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
    Agarwal, S.
    Zaman, T.
    Handa, R.
    SINGAPORE MEDICAL JOURNAL, 2009, 50 (07) : 686 - 692
  • [28] Real-world clinical experience of biological disease modifying anti-rheumatic drugs in Malaysia rheumatoid arthritis patients
    Bee Eng Tan
    Ai Lee Lim
    Sow Lai Kan
    Chong Hong Lim
    Esther Ee Ling Tsang
    Shereen Suyin Ch’ng
    Nadiah Mohd Noor
    Nurulraziquin Mohd Jamid
    Cheng Lay Teh
    Rachel Joshua Thundyil
    Yet Lin Loh
    Hwee Cheng Chong
    Swee Gaik Ong
    Asmahan Mohamed Ismail
    Yvonne Y. L. Lee
    Suk Chyn Gun
    Rheumatology International, 2017, 37 : 1719 - 1725
  • [29] Real-world clinical experience of biological disease modifying anti-rheumatic drugs in Malaysia rheumatoid arthritis patients
    Tan, Bee Eng
    Lim, Ai Lee
    Kan, Sow Lai
    Lim, Chong Hong
    Tsang, Esther Ee Ling
    Ch'ng, Shereen Suyin
    Noor, Nadiah Mohd
    Jamid, Nurulraziquin Mohd
    Teh, Cheng Lay
    Thundyil, Rachel Joshua
    Loh, Yet Lin
    Chong, Hwee Cheng
    Ong, Swee Gaik
    Ismail, Asmahan Mohamed
    Lee, Yvonne Y. L.
    Gun, Suk Chyn
    RHEUMATOLOGY INTERNATIONAL, 2017, 37 (10) : 1719 - 1725
  • [30] Real-World Switching and Discontinuation Patterns for Biologic Disease-Modifying Antirheumatic Drugs in Patients with Active Psoriatic Arthritis in Japan
    Erik, Lars
    Soliman, Ahmed
    Nunag, Dominic
    Lippe, Ralph
    Davis, Matthew
    Kishimoto, Mitsumasa
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4444 - 4445
12345